Dr. Kayla Cornett to Present Groundbreaking CMT Wearable Sensor Study at MDA Clinical and Scientific Conference

by | Jan 17, 2025 | 0 comments

On March 19th, at the MDA Clinical and Scientific Conference in Dallas, TX, Dr. Cornett will present exciting findings from the wearable sensor study conducted in collaboration with HNF’s partner, BioSensics. This innovative research highlights the potential of wearable technology to transform how disease progression and therapy effectiveness are measured for individuals with CMT.

Looking for new patients to participate in the BioSensics Wearable Study. Join us in Nashville, TN, April 24-26th.

Learn more on this topic

Related Blog Posts

HNF is Reshaping Drug Repurposing for CMT

HNF is Reshaping Drug Repurposing for CMT

HNF has partnered with Rarebase, a public benefit precision medicine company that has screened a large library of FDA approved small molecules to identify candidates for various types of CMT. Their tech-enabled drug discovery platform is called Function™. There are many published discoveries on the genetic cause of many types of CMT, including an understanding of the basic mechanism of disease and potential targets for FDA-approved drug repurposing. It is this understanding that allows HNF and Rarebase to target the genetic root cause of CMT.

The Key Role CMT Patients Play in Research

The Key Role CMT Patients Play in Research

Without your participation, researchers won’t have the essential patient information to develop drugs, gene therapies, and clinical trials for Charcot-Marie-Tooth and other Inherited Neuropathies. In addition, as GRIN grows, we gain greater insights from you as patients to help accelerate therapies for Charcot-Marie-Tooth (CMT) and Inherited Neuropathies.

Join the conversation

Leave a Comment

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

Newsletter

Join for notifications on events, campaigns, & news